Efficacy of bevacizumab combined with niraparib in the treatment of platinum-sensitive recurrent advanced ovarian cancer
Objective To investigate the therapeutic effect of niraparib combined with bevacizumab on platinum-sensitive recurrent advanced ovarian cancer.Methods A total of 112 cases of platinum-sensitive recurrent advanced ovarian cancer were select-ed and divided into study group and control group by random number table method,with 56 cases in each group.The patients in the con-trol group was treated with bevacizumab,and the patients in the study group was treated with niraparib and bevacizumab.After 4 courses of treatment,the clinical efficacy,human epididymal protein 4(HE4),carbohydrate antigen 125(CA1 25)and adverse drug reactions were evaluated in both groups.The patients'survival status of two years were conducted.Results The objective response rate was 73.21％in the study group and 53.57％in the control group,with a significantly higher objective response rate in the study group(P＜0.05).The disease control rate was 80.36％in the study group and 73.21％in the control group,with no significant difference between the two groups(P＞0.05).After treatment,the levels of serum AFP and CA125 were significantly reduced in both groups(P＜0.05).There was no significant difference in the incidence of leukopenia,bone marrow suppression,liver and kidney damage,and gastrointestinal adverse reactions between the two groups(P＞0.05).The median progression free survival time in the study group and the control group was 23.10 months(95％CI:17.01～28.99)and 13.95 months(95％CI:10.72～17.29),respectively.There was a statistically significant difference in the median progression free survival curve between the two groups(x2=5.907,P＜0.05).Conclusion The combination of niraparib and bevacizumab in the treatment of platinum sensitive recurrent advanced ovarian cancer can effectively regulate tumor markers in patients,improve the objective response rate,prolong patient survival and exhibit good safety.
万方数据
维普
